The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)

被引：3
|
作者：
Kadowaki, S. [1 ]
Sakai, D. [2 ]
Kawabata, R. [3 ]
Hara, H. [4 ]
Yasui, H. [5 ]
Takahashi, M. [6 ]
Hirao, M. [7 ]
Imai, H. [8 ]
Minashi, K. [9 ]
Kawakami, T. [10 ]
Satake, H. [11 ]
Matsuyama, J. [12 ]
Sakamoto, Y. [13 ]
Sawada, K. [14 ]
Kataoka, M. [15 ]
Kawakami, H. [16 ]
Shimokawa, T. [17 ]
Boku, N. [18 ]
Satoh, T. [19 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[2] Osaka Int Canc Inst, Dept Med Oncol, Osaka, Japan
[3] Osaka Rosai Hosp, Dept Gastrointestinal Surg, Sakai, Osaka, Japan
[4] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[5] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan
[6] Yokohama Municipal Citizens Hosp, Dept Gatroenterol Surg, Yokohama, Kanagawa, Japan
[7] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan
[8] Tohoku Univ Hosp, Dept Med Oncol, Sendai, Miyagi, Japan
[9] Chiba Canc Ctr Hosp, Clin Trial Promot Dept, Chiba, Japan
[10] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[11] Kansai Med Univ Hosp, Canc Treatment Ctr, Hirakata, Osaka, Japan
[12] Higashiosaka City Med Ctr, Dept Gastroenterol Surg, Higashiosaka, Osaka, Japan
[13] Osaki Citizen Hosp, Dept Med Oncol, Osaki, Japan
[14] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Japan
[15] Nagoya Med Ctr, Natl Hosp Org, Dept Surg, Nagoya, Aichi, Japan
[16] Kindai Univ, Dept Med Oncol, Fac Med, Osakasayama, Japan
[17] Wakayama Med Univ, Clin Study Support Ctr, Fac Med, Wakayama, Japan
[18] Univ Tokyo, Inst Med Sci, IMS Hosp, Dept Oncol & Gen Med, Tokyo, Kanagawa, Japan
[19] Osaka Univ Hosp, Ctr Canc Genom & Precis Med, Suita, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA76
引用
收藏
页码：S1317 / S1318
页数：2
相关论文
共 50 条
  • [41] A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer
    Underhill, Craig R.
    Goldstein, David
    Gorbunova, Vera A.
    Biakhov, Mikhail Y.
    Bazin, Igor S.
    Melemed, Allen
    Hossain, Anwar
    Granov, Dmitry A.
    ANNALS OF ONCOLOGY, 2006, 17 : 118 - 118
  • [42] Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
    Cartwright, Thomas
    Kuefler, Paul
    Cohn, Allen
    Hyman, William
    Berger, Maury
    Richards, Donald
    Vukelja, Svetislava
    Nugent, John E.
    Ruxer, Robert L., Jr.
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 390 - 397
  • [43] E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).
    Hochster, Howard S.
    Catalano, Paul J.
    Mitchell, Edith P.
    Cohen, Deirdre Jill
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial
    Schmittel, A. H.
    Sebastian, M.
    von Weikersthal, L. Fischer
    Gauler, T.
    Hortig, P.
    Fischer, J. R.
    Link, H.
    Binder, D.
    Eberhardt, W.
    Keilholz, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] RANDOMIZED PHASE II TRIAL OF S-1 PLUS IRINOTECAN VERSUS S-1 PLUS PACLITAXEL AS FIRST-LINE TREATMENT FOR ADVANCED GASTRIC CANCER (OGSG0402)
    Fujitani, K.
    Takiuchi, H.
    Sugimoto, N.
    Imamura, H.
    Iijima, S.
    Imano, M.
    Kimura, Y.
    Kurokawa, Y.
    Tsujinaka, T.
    Furukawa, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 256 - 256
  • [46] Randomized Phase II Trial of S-1 plus Irinotecan Versus S-1 plus Paclitaxel as First-line Treatment for Advanced Gastric Cancer (OGSG0402)
    Sugimoto, Naotoshi
    Fujitani, Kazumasa
    Imamura, Hiroshi
    Uedo, Noriya
    Iijima, Shohei
    Imano, Motohiro
    Shimokawa, Toshio
    Kurokawa, Yukinori
    Furukawa, Hiroshi
    Goto, Masahiro
    ANTICANCER RESEARCH, 2014, 34 (02) : 851 - 857
  • [47] CHARTA: FOLFOX plus bevacizumab plus /- irinotecan in advanced colorectal cancer (CRC)-Final results of the randomized phase II trial of the AIO (KRK 0209).
    Schmoll, Hans-Joachim
    Garlipp, Benjamin
    Junghanss, Christian
    Leithaeuser, Malte
    Vogel, Arndt
    Schaefers, Michael
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Florschuetz, Axel
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Steighardt, Joerg
    Meinert, Fabian Maximilian
    Cygon, Franziska
    Stein, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [48] Randomized phase II trial of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) for advanced gastric cancer
    Shin, D.
    Lee, S.
    Park, S.
    Park, J.
    Cho, E.
    Lee, J.
    Lee, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial
    Valle, J. W.
    Bousmans, N.
    Zhang, W.
    Walgren, R. A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2016, 27 : vi240
  • [50] Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001+irinotecan vs. regorafenib plus irinotecan in third/fourth-line colorectal cancer.
    Reid, Tony R.
    Abrouk, Nacer
    Oronsky, Bryan
    Caroen, Scott
    Fisher, George A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 97 - 97
12345